Not Medicare Enrolled

Dr. Lauren Ritterhouse Casariego, M.D., PH.D.

Molecular Genetic Pathology (Pathology) Physician · Boston, MA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Consulting-driven
55 FRUIT ST, Boston, MA 02114
6177262967
In practice since 2013 (12 years)
NPI: 1508295874 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Ritterhouse Casariego from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ritterhouse Casariego? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Ritterhouse Casariego

Dr. Lauren Ritterhouse Casariego is a molecular genetic pathology physician in Boston, MA, with 12 years of NPI registration. Based on federal Medicare data, Dr. Ritterhouse Casariego performed 164 Medicare services across 138 unique beneficiaries.

Between the years covered by Open Payments, Dr. Ritterhouse Casariego received a total of $43,202 from 9 pharmaceutical and/or device companies across 32 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in molecular genetic pathology (pathology) physician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Ritterhouse Casariego is High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 12 years in practice ▲ 164 Medicare services $43,202 industry payments

Medicare Practice Summary

Medicare Utilization ↗
164
Medicare services
1.0× state median for molecular genetic pathology (pathology) physician
138
Unique beneficiaries
$33
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~14 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Manual microscopic genetic analysis of tissue
A laboratory test that manually examines tissue samples under a microscope to analyze genetic material. This initial procedure involves direct visual inspection to identify specific genetic characteristics.
 84 $34 $221
Molecular pathology test interpretation
A physician reviews and interprets the results of a molecular pathology test to provide a diagnostic report.
 54 $39 $188
Manual specimen preparation
A healthcare provider manually prepares a medical specimen for testing or analysis.
 26 $20 $182
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2023 ↗
$43,202
Total received (2018-2023)
Avg $7,200/year across 6 years
Top 33% in MA for molecular genetic pathology (pathology) physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
9
Companies
32
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$39,202 (90.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,000 (9.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2023
$7,646
2022
$11,132
2021
$13,405
2020
$3,630
2019
$1,888
2018
$5,501

Payments by company (2023)

Consulting
Speaking
Meals & Travel
Research
Life Technologies Corporation
$4,000
Astellas Pharma US Inc
$3,646
Top 3 companies account for 100.0% of 2023 payments
All-time payments by company (2018-2023) ›
GENZYME CORPORATION
$10,711
Merck Sharp & Dohme Corporation
$7,085
E.R. Squibb & Sons, L.L.C.
$5,501
Astellas Pharma US Inc
$4,067
Life Technologies Corporation
$4,000
EMD Serono, Inc.
$3,900
AstraZeneca Pharmaceuticals LP
$3,630
AstraZeneca UK Limited
$2,420
Eli Lilly and Company
$1,888
Top 3 companies account for 53.9% of all-time payments
Associated products mentioned in payments ›
IMFINZI · Tepmetko
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (91%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Looking for a molecular genetic pathology physician in Boston?
Compare molecular genetic pathology physicians in the Boston area by procedure volume, costs, and industry payment transparency.
Browse molecular genetic pathology physicians nearby

Geographic Context

Molecular genetic pathology physicians within 10 mi
7
Per 100K population
0.9
County median income
$92,859
Nearest hospital
MASSACHUSETTS GENERAL HOSPITAL
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment — Not enrolled N/A
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2023
Disciplinary History — Not public N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Ritterhouse Casariego is a mixed practice specialist, with consulting-driven industry engagement.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Ritterhouse Casariego experienced with manual microscopic genetic analysis of tissue?
Based on Medicare claims data, Dr. Ritterhouse Casariego performed 84 manual microscopic genetic analysis of tissue services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ritterhouse Casariego receive payments from pharmaceutical companies?
Yes. Dr. Ritterhouse Casariego received a total of $43,202 from 9 companies across 32 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ritterhouse Casariego's costs compare to other molecular genetic pathology physicians in Boston?
Dr. Ritterhouse Casariego's average Medicare payment per service is $33. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Ritterhouse Casariego) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Molecular Genetic Pathology Physicians in Boston
Browse molecular genetic pathology physicians in Boston ranked by procedure volume and transparency data.
Highest volume
Top Molecular Genetic Pathology Physicians in MA
Molecular genetic pathology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Molecular Genetic Pathology Physicians in MA
Which MA molecular genetic pathology physicians receive the most from drug and device companies.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →